Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
NCT ID: NCT05158387
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1172 participants
INTERVENTIONAL
2022-02-07
2026-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT05166889
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06040086
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
NCT04631016
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tozorakimab Dose 1
Dosing subcutaneously tozorakimab Dose 1 and placebo
Tozorakimab
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
Tozorakimab Dose 2
Dosing subcutaneously tozorakimab Dose 2
Tozorakimab
Administered subcutaneously tozorakimab Dose 2 through Week 52.
Placebo
Dosing subcutaneously with equivalent volume to tozorakimab
Placebo
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tozorakimab
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
Tozorakimab
Administered subcutaneously tozorakimab Dose 2 through Week 52.
Placebo
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented diagnosis of COPD for at least one year prior to enrolment.
3. Post BD FEV1/FVC \< 0.70 and post-BD FEV1 \>20% of predicted normal value.
4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.
6. Smoking history of ≥ 10 pack-years.
7. CAT total score ≥10, with each of the phlegm (sputum) and cough items with a score ≥ 2
Exclusion Criteria
2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.
3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.
6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
8. Significant COVID-19 illness within the 6 months prior to enrolment.
9. Unstable cardiovascular disorder.
10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.
12. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C)
13. Evidence of active liver disease, including jaundice during screening.
14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
15. Participants who have evidence of active TB.
16. Participants that have previously received tozorakimab.
17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
18. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.
40 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Sheffield, Alabama, United States
Research Site
Lincoln, California, United States
Research Site
Newport Beach, California, United States
Research Site
Northridge, California, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Newark, Delaware, United States
Research Site
Bay Pines, Florida, United States
Research Site
Cape Coral, Florida, United States
Research Site
Pensacola, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Winter Park, Florida, United States
Research Site
Macon, Georgia, United States
Research Site
Greenwood, Indiana, United States
Research Site
Bowling Green, Kentucky, United States
Research Site
White Marsh, Maryland, United States
Research Site
North Dartmouth, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Farmington Hills, Michigan, United States
Research Site
Grand Rapids, Michigan, United States
Research Site
Buffalo, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tulsa, Oklahoma, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Rock Hill, South Carolina, United States
Research Site
Amarillo, Texas, United States
Research Site
Boerne, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
McKinney, Texas, United States
Research Site
Tomball, Texas, United States
Research Site
Webster, Texas, United States
Research Site
Williamsburg, Virginia, United States
Research Site
Cudahy, Wisconsin, United States
Research Site
Campbelltown, , Australia
Research Site
Frankstown, , Australia
Research Site
Macquarie University, , Australia
Research Site
Melbourne, , Australia
Research Site
Nedlands, , Australia
Research Site
Southport, , Australia
Research Site
Spearwood, , Australia
Research Site
Wollongong, , Australia
Research Site
Woodville South, , Australia
Research Site
Blumenau, , Brazil
Research Site
Botucatu, , Brazil
Research Site
Brasília, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
São Bernardo do Campo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Curicó, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Talca, , Chile
Research Site
Baotou, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changchun, , China
Research Site
Changde, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Chongqing, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Haikou, , China
Research Site
Hangzhou, , China
Research Site
Hefei, , China
Research Site
Hohhot, , China
Research Site
Kunming, , China
Research Site
Linhai, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Ningbo, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shengyang, , China
Research Site
Shenyang, , China
Research Site
Shenzhen, , China
Research Site
Shenzhen, , China
Research Site
Shijiazhuang, , China
Research Site
Suzhou, , China
Research Site
Taiyuan, , China
Research Site
Tianjin, , China
Research Site
Wuhan, , China
Research Site
Wuxi, , China
Research Site
Xiamen, , China
Research Site
Xuzhou, , China
Research Site
Xuzhou, , China
Research Site
Yangzhou, , China
Research Site
Yinchuan, , China
Research Site
Zhanjiang, , China
Research Site
Zunyi, , China
Research Site
Barranquilla, , Colombia
Research Site
Ibagué, , Colombia
Research Site
Rionegro, , Colombia
Research Site
Zipaquirá, , Colombia
Research Site
Brest, , France
Research Site
Dijon, , France
Research Site
Grenoble, , France
Research Site
Lyon, , France
Research Site
Marseille, , France
Research Site
Montivilliers, , France
Research Site
Montpellier, , France
Research Site
Pessac, , France
Research Site
Saint-Herblain, , France
Research Site
Toulouse, , France
Research Site
Ahrensburg, , Germany
Research Site
Bamberg, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Cologne, , Germany
Research Site
Darmstadt, , Germany
Research Site
Halle, , Germany
Research Site
Marburg, , Germany
Research Site
München, , Germany
Research Site
München-Pasing, , Germany
Research Site
Peine, , Germany
Research Site
Alexandroupoli, , Greece
Research Site
Athens, , Greece
Research Site
Exohi Thessaloniki, , Greece
Research Site
Ioannina, , Greece
Research Site
Pátrai, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Ashkelon, , Israel
Research Site
Beersheba, , Israel
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Rehovot, , Israel
Research Site
Tel Aviv, , Israel
Research Site
Bari, , Italy
Research Site
Massa, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Roma, , Italy
Research Site
Salerno, , Italy
Research Site
San Donà di Piave, , Italy
Research Site
Sassari, , Italy
Research Site
Statte, , Italy
Research Site
Telese Terme, , Italy
Research Site
Tradate, , Italy
Research Site
Vercelli, , Italy
Research Site
Verona, , Italy
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Baguio City, , Philippines
Research Site
Cebu City, , Philippines
Research Site
Iloilo City, , Philippines
Research Site
Bialystok, , Poland
Research Site
Bialystok, , Poland
Research Site
Bychawa, , Poland
Research Site
Bydgoszcz, , Poland
Research Site
Katowice, , Poland
Research Site
Krakow, , Poland
Research Site
Lublin, , Poland
Research Site
Ostrowiec Świętokrzyski, , Poland
Research Site
Ostróda, , Poland
Research Site
Poznan, , Poland
Research Site
Poznan, , Poland
Research Site
Rzeszów, , Poland
Research Site
Skierniewice, , Poland
Research Site
Sosnowiec, , Poland
Research Site
Wroclaw, , Poland
Research Site
Ponce, , Puerto Rico
Research Site
Brasov, , Romania
Research Site
Bucharest, , Romania
Research Site
Cluj-Napoca, , Romania
Research Site
Constanța, , Romania
Research Site
Timișoara, , Romania
Research Site
Penza, , Russia
Research Site
Saratov, , Russia
Research Site
Hsinchu, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Yunlin, , Taiwan
Research Site
Bang Kra So, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Muang,, , Thailand
Research Site
Muang, , Thailand
Research Site
Mueang, , Thailand
Research Site
Nakhon Ratchasima, , Thailand
Research Site
Bradford, , United Kingdom
Research Site
Corby, , United Kingdom
Research Site
Corby, , United Kingdom
Research Site
Enfield, , United Kingdom
Research Site
Hampshire, , United Kingdom
Research Site
High Wycombe, , United Kingdom
Research Site
Northwood, , United Kingdom
Research Site
Preston, , United Kingdom
Research Site
Shipley, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-003771-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D9180C00004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.